Martin Barraud
- French biotech Valneva SE (NASDAQ:VALN) announced Thursday a partnership with Australian company CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF) to commercialize three of its brand-name vaccines in Germany, replacing a previous deal with Bavarian Nordic (BAVN).
- Under the agreement, CSL unit CSL Seqirus will distribute and market Valneva’s (NASDAQ:VALN) Ixchiq chikungunya vaccine starting from July 2025 and its cholera/ETEC shot Dukoral and Ixiaro Japanese Encephalitis vaccine from January 2026.
- The new three-year deal, which includes terms for minimum annual purchasing quantities, comes as the company’s 2021 marketing and distribution agreement with Bavarian Nordic (OTCPK:BVNKF) (OTCPK:BVNRY) is expected to conclude at the end of this year.
- The agreement is seen as a major boost to Valneva’s (NASDAQ:VALN) efforts to increase its product sales to €170M-€180M this year from €48.6M in Q1 2025. Financial terms of the agreement were not disclosed.
More on Valneva, Bavarian Nordic, etc.
- Bavarian Nordic A/S (BVNKF) Q1 2025 Earnings Call Transcript
- Bavarian Nordic A/S 2025 Q1 – Results – Earnings Call Presentation
- Valneva SE (VALN) Q1 2025 Earnings Call Transcript
- CDC vaccine panel recommends only thimerosal-free flu vaccines
- Former head of anti-vaccine group to make presentation at ACIP meeting